Winfield Associates’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Winfield Associates’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,650	Closed	-$228K	–	140
2020 Q2	$228K	Sell	12,650 -825	-6%	-$11.5K	0.12%	110
2020 Q1	$96K	Buy	13,475 +500	+4%	+$6.24K	0.06%	120
2019 Q4	$310K	Buy	12,975 +1,530	+13%	+$42.2K	0.14%	102
2019 Q3	$307K	Buy	+11,445	New	+$321K	0.15%	102

Winfield Associates's PTLA Position: Q3 2020 in Review

Winfield Associates sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 12,650 shares — an estimated $228K sold.

Winfield Associates first reported a position in PTLA in Q3 2019 and held it in 4 quarters. The position peaked at $310K in Q4 2019. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

Winfield Associates reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Winfield Associates sold 12,650 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $228K.
Winfield Associates first reported a position in Portola Pharmaceuticals, Inc. in Q3 2019 and held it in 4 quarters.
Winfield Associates's Portola Pharmaceuticals, Inc. position peaked at $310K in Q4 2019.
0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Winfield Associates's 13F filing for Q3 2020, filed 14 Oct 2020.